Monthly Archives:

Phase 2 IMAAGEN Trial Results Promising

“The IMAAGEN trial is a phase 2 study in patients who are in an earlier stage of disease than the COU-AA-302 trial. These are patients who have castration-resistant prostate cancer, but no metastases. Lethal prostate cancer is the confluence of castration-resistant disease and metastases, so these patients have only one of those problems. IMAAGEN showed a 90 plus percent response ... Read More »

Zytiga® + Low-Dose Predisone Lower PSA Levels in MO-CRPC Patients

Maui—In the IMAAGEN  (Impact of Abiraterone Acetate in Prostate Specific Antigen) core study, patients with non-metastatic castration-resistant prostate cancer (MO-CRPC) had statistically significant reductions in prostate-specific antigen (PSA) levels at 6 months with a therapy regimen of abiraterone acetate (Zytiga®) plus prednisone (5 mg twice daily). The primary end point was the proportion of patients with a ≥50% reduction in ... Read More »

Prostate Cancer at the Western Section AUA Maui 2014

On October 29, the Prostate Cancer Session will include a State of the Art Lecture from Leonard Marks, MD, from UCLA. Dr. Marks is a professor of urology at the David Geffen School of Medicine at UCLA. He was founder and medical director of Urological Sciences Research Foundation, a California non-profit organization (501c3), from its inception in 1992 through year-end 2008, ... Read More »

RNA CCP Score Provides Significant Prognostic Information

Rancho Mirage, CA—In a study conducted by Jack M. Cuzick, PhD, and colleagues at the Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom, the researchers found that cell cycle progression (CCP) score can be used to determine which patients with prostate cancer can be safely managed with a conservative policy, thus avoiding radical treatment. Results of ... Read More »

GTx-758 Effective and Well Tolerated

Rancho Mirage, CA—Preliminary findings of a phase II study demonstrated that the majority of patients on an luteinizing hormone-releasing hormone (LHRH) had suboptimal levels of free testosterone (T) that were further lowered by administration of GTx-758 (Capesaris®). Robert H. Getzenberg, PhD, and colleagues presented the results during a poster session at the South Central Section of the American Urological Association ... Read More »

Cycle Cell Progression Score Influences Prostate Cancer Treatment Decisions

Rancho Mirage, CA—The cell cycle progression (CCP) score report adds meaningful information for clinicians making treatment decisions for patients with prostate cancer. That was among the findings of a prospective study conducted by E. David Crawford, MD, and colleagues. Study results were reported during a poster session at the South Central Section of the American Urological Association 93rd Annual Meeting. ... Read More »